Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: A phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

British Journal of Cancer

Volumn 107, Issue 5, 2012, Pages 808-813

  Beer, T M ^a   Smith, D C ^b   Hussain, A ^c   Alonso, M ^d   Wang, J ^e   Giurescu, M ^f   Roth, K ^f   Wang, Y ^g  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^d Children Hospital of Córdoba   (Argentina)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f BAYER PHARMA AG   (Germany)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

clinical trial; epothilones; phase II; prednisone; prostatic neoplasms

Indexed keywords

PREDNISONE; SAGOPILONE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD TOXICITY; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FATIGUE; GLEASON SCORE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOTHIAZOLES; EPOTHILONES; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 84865418670     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.339     Document Type: Article

References (23)

1. Altaha R, Fojo T, Reed E, Abraham J (2002) Epothilones: a novel class of non-taxane microtubule-stabilizing agents. Curr Pharm Des 8: 1707-1712 (Pubitemid 34846197)
2. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55: 2325-2333
3. Buch-Hansen TZ, Bentzen L, Hansen S, Hoeyer M, Jensen NV, Saxe C, Sengeloev L (2010) Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer Chemother Pharmacol 66: 295-301
4. Cancer Research UK (2010) Prostate cancer risks and causes. Available at:http://www.cancerhelp.org.uk/type/prostate-cancer/about/prostate-cancer- risks-and-causes Accessed 20 July 2011
5. Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, Ko YJ, Sridhar SS, Weber D, Saad F (2012) A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol 23: 53-58
6. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after doc-etaxel treatment: a randomised open-label trial. Lancet 376: 1147-1154
7. DeVita VT, Lawrence TS, Rosenberg SA (2008) Cancer: Principles and Practice of Oncology. 8th edn. Lippincott Williams & Wilkins: Philadelphia
8. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, DeLaCruz A, Scher HI, Kelly WK (2005) Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23: 1439-1446
9. Gauler TC, Christoph DC, Gamarra F, Fuhr H, Gonschorek C, Giurescu M, Frickhofen N, Huber RM, Schuler M, Eberhardt WEE (2008) Phase I trial of the novel epothilone sagopilone (ZK-EPO) in combination with cisplatin as first-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC). J Clin Oncol 26: 19081
10. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G (2008) Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68: 5301-5308
11. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR (2009) Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 20: 492-497
12. Hussain M, Tangen CM, Lara Jr PN, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED (2005) Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 23: 8724-8729 (Pubitemid 46211517)
13. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB (2006) Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 45: 7942-7948 (Pubitemid 44912747)
14. McMeekin S, Patel R, Verschraegen C, Celano P, Burke J, Plaxe S, Ghatage P, Giurescu M, Stredder C, Wang Y (2008) Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. Ann Oncol 19(Suppl 8) Abstract 665O, pviii211
15. Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM (2007) Diethylstilbestrol and docetaxel: a phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 110: 996-1002 (Pubitemid 47312864)
16. National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer V.4.2011. Available at: http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf Accessed 20 July 2011
17. Petrylak DP, Tangen CM, Hussain MHA, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520 (Pubitemid 39315318)
18. Rustin GJ, Reed NS, Jayson G, Ledermann JA, Adams M, Stredder C, Wagner A, Giurescu M, The ZK-EPO Study Group in Platinum-Resistant Ovarian Cancer (2007) Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer. J Clin Oncol 25: 5527
19. Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H, Thiel E, Kühnhardt D (2010) Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 21: 633-639
20. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, for the TAX327 Investigators (2004) Docetaxel plus prednisone or mitox-antrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512 (Pubitemid 39315317)
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216 (Pubitemid 30099779)
22. Vishnu P, Tan WW (2010) Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 3: 39-51
23. Wenk D, DeConti RC, Urbas P, Andrews S, Sondak VK, Maker N, Weber JS, Daud AI (2008) Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma. J Clin Oncol 26: 9046